Abby Hardy, Author at BioTuesdays

Developments

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Aprea Therapeutics (NASDAQ:APRE) received FDA breakthrough designation for APR-246, in combination with azacytidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible tumor suppressor protein p53...

January 30, 2020

Developments

Pulmatrix gets fast track designation for Pulmazole

Pulmatrix (NASDAQ:PULM) received FDA fast track designation for Pulmazole, an inhaled itraconazole antifungal for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The safety...

January 30, 2020

Developments

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

The FDA cleared VistaGen Therapeutics’ (NASDAQ:VTGN) IND for AV-101 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease, enabling the company to proceed with Phase 2...

January 30, 2020

Developments

Hepion reports positive results of CRV431 in expanded human liver study

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its non-alcoholic steatohepatitis (NASH) candidate, CRV431, demonstrated superior antifibrotic efficacy in an expanded human liver study. The study design and its...

January 28, 2020

Developments

HLS Therapeutics to launch Vascepa in Canada next month

HLS Therapeutics (TSX:HLS) reported that its cardiovascular drug, Vascepa, will be available in Canada on or about February 18, 2020. Vascepa was approved by Health Canada at the end of 2019. HLS noted that the approval...

January 28, 2020

Developments

Akcea reports positive topline Phase 2 data from cardiometabolic disease trial

Akcea Therapeutics (NASDAQ:AKCA) reported positive topline results from its Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, Type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). ...

January 28, 2020

Feature

Inagene personalizing pain management with comprehensive genetic test

Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...

January 28, 2020

Markets

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

January 27, 2020

Developments

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported its 2019 i/Blue Imaging System development achievements and upcoming 2020 milestones. “2019 was a momentous year for the Company as...

January 23, 2020

Developments

Genprex gets fast track designation for lung cancer gene therapy

The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...

January 21, 2020

Author - Abby Hardy

Aprea Therapeutics gets breakthrough therapy designation for myelodysplastic syndrome treatment

Pulmatrix gets fast track designation for Pulmazole

FDA clears VistaGen’s IND for Phase 2 levodopa-induced dyskinesia study

Hepion reports positive results of CRV431 in expanded human liver study

HLS Therapeutics to launch Vascepa in Canada next month

Akcea reports positive topline Phase 2 data from cardiometabolic disease trial

Inagene personalizing pain management with comprehensive genetic test

Dawson James ups CollPlant PT to $15 from $9

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Genprex gets fast track designation for lung cancer gene therapy

Subscribe